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Aim To assess the diagnostic value of neutrophil-to-lym-
phocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) 
in lung cancer (LC). We compared the ratios between 
healthy participants and all LC patients, as well patients 
with different pathohistological LC subtypes.
Methods We retrieved the data on neutrophil, lympho-
cyte, and platelet levels in 449 patients with different 
pathohistological LC subtypes (non-small cell LC, small-
cell LC, atypical or metastatic LC, neuroendocrine, and 
sarcomatoid carcinoma) and 47 healthy controls. NLR and 
PLR were calculated by dividing the absolute number of 
neutrophils or platelets with the absolute number of lym-
phocytes.
Results There were significant differences in both NLR 
and PLR (P < 0.001) between all LC patients and the con-
trol group, but there were no differences between patients 
with different LC subtypes. Reciever operating character-
istics analysis for NLR showed the optimal cut-off value of 
2.71, with a sensitivity of 77.05% and specificity of 87.23%. 
The optimal cut-off value for PLR was 182.31, with a sensi-
tivity of 51.09% and specificity of 91.49%.
Conclusion The results showed that the NLR and PLR may 
have added value in the early diagnosis of LC, but further 
research is needed to confirm these results.
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Malignant diseases are among the most common causes of 
death (1), with lung carcinomas (LC) being the most diag-
nosed malignant disease and a leading cause of death from 
malignant disease in developed countries in 2012 (2).
Many of the carcinomas grow at the site of the infection, 
chronic irritation, and inflammation, and the most recent 
research shows that systemic inflammatory reaction plays 
a very important role in the development and spread of tu-
mor cells. Secretion of different cytokines stimulated by in-
flammation induces angiogenesis and tumor invasion, also 
damaging the DNA. Tumor cells secrete different chemok-
ines that attract neutrophils, monocytes, and lymphocytes. 
At the beginning of tumor growth, these cells create an 
environment that promotes growth and stimulates angio-
genesis. Although inflammatory response should have an 
antitumor effect, in patients with developed tumors this 
response is changed (3). A recent study also has shown 
that leukocytes, neutrophils, alpha-1, and alpha-2 protein 
fractions are increased in non-small-cell lung cancer (4).
Neutrophils, the most numerous leukocytes in the periph-
eral blood, besides having a role in destroying tumor cells, 
also play an important role in tumor growth stimulation 
by secreting different cytokines, growth factors, proteases, 
and other molecules (5). On the other hand, lymphocytes 
protect the organism from tumor cells by blocking their 
proliferation and migration (2). Platelets, by secreting dif-
ferent growth factors, play an important role in inflamma-
tion, tissue regeneration, and immunologic response (6).
Although the therapy of LC has recently seen substantial 
advances, the early diagnostic accuracy of this condition 
remains unsatisfying. Therefore, in order to better diagnose 
LC patients, new markers are needed.
An imbalance between neutrophils and lymphocytes 
takes place due to hypoxia and necrosis caused by tumor 
cells, which is also connected to antiapoptosis. The studies 
so far (7-10) have found that NLR and PLR are good inflam-
matory response follow-up markers and predictive surviv-
al markers in patients with different carcinomas, including 
LC. Also, they can be easily obtained in everyday practice, 
without additional costs (11,12). However, their diagnos-
tic value remained unexplained. This is why we decided to 
study diagnostic value of NLR and PLR in early diagnosis 
of different LC subtypes. Our hypothesis was that there 
was a difference in NLR and PLR between LC patients and 
healthy participants, and between patients with differ-
ent LC subtypes. To the best of our knowledge, this 
research is the first to include all other pathohistological LC 
subtypes in the assessment of the diagnostic significance 
of NLR and PLR.
PaTIeNTS aND MeThODS
The absolute number of neutrophil granulocytes, lympho-
cytes, and platelets of LC patients diagnosed between Jan-
uary 2012 and December 2015 at the Clinic for Lung Dis-
eases “Jordanovac,” University Hospital Centre Zagreb, and 
Clinical Hospital “Dubrava,” (n = 449) were retrieved from 
the hospital registries. We included only samples collect-
ed when LC was diagnosed for the first time, before any 
therapies (surgery, chemo- and radiotherapy) were initiat-
ed. The patients were divided into groups according to the 
pathohistologic cancer subtype: 1) small-cell LC (SCLC); 2) 
non-small cell LC (NSCLC); 3) atypical and metastatic LC; 4) 
neuroendocrine LC, and 5) sarcomatoid LC. Patients with 
NSCLC were further divided into: 2a) adenocarcinoma; 2b) 
planocellular carcinoma; 2c) non-classified carcinoma.
Controls were selected from the pool of employees of the 
Clinical Hospital “Dubrava” who underwent routine annual 
general medical examinations, and they were sex and age 
matched with the LC patients (n = 47). They had no history 
of any pulmonary or other diseases that could affect either 
NLR or PLR. The study was approved by the Ethics Commit-
tee of the Clinical Hospital “Dubrava.”
All blood samples were collected in vacutainer test tubes 
with potassium EDTA (kEDTA) as an anticoagulant. Differ-
ential blood counts (DBC) were performed at the Clinic for 
Lung Diseases “Jordanovac” using the hematology analyz-
er Coulter LH 750 (Beckman Coulter, Miami, FL, USA), and 
at the Clinical Hospital “Dubrava” using the Siemens ADVIA 
2120i (Siemens Diagnostics, Tarrytown, NY, USA). NLR and 
PLR were calculated by dividing the absolute number of 
neutrophils or platelets with the absolute number of lym-
phocytes.
Statistical analysis
The normality of the distribution was tested using the 
Kolmogorov-Smirnov test. NLR and PLR values are sum-
marized as median with absolute range. Between-group 
differences were tested using the one-way analysis of vari-
ance (ANOVA) and Student-Newman-Keuls’s post-hoc test. 
Reciever operating characteristics (ROC) curves were used 
to calculate the optimal cut-off values for NLR and PLR to 
discriminate between LC patients and healthy participants, 
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with an optimal proportion of false positive and false-neg-
ative results. All tests were two-sided and the significance 
level was set at P < 0.05. Statistical analyses were performed 
using MedCalc (MedCalc ver. 14, Mariakerke, Belgium).
ReSuLTS
The total number of patients who met the inclusion crite-
ria was 449, but due to incomplete data, 61 were excluded, 
so the final number of analyzed patients was 388. Groups 
with neuroendocrine, sarcomatoid, metastatic, and atypi-
cal LC were not included in the statistical analysis due to a 
small number of participants. There were no differences in 
sex and age between cases and controls (289/388 [74.4%] 
men vs 37/47 [78.7%] men; 64 ± 9 years vs60 ± 6 years, re-
spectively).
NLR and PLR values by groups are summarized in Table 1. 
ANOVA showed significant differences for both NLR and 
PLR (P < 0.001), and post-hoc differences were significant 
for all LC subtypes compared to the control group, while 
the differences between the LC subtypes were not signifi-
cant (Table 1).
ROC analysis (Figure 1) was performed only for the NSCLC 
and SCLC subgroups, and other groups were excluded 
from the analysis due to the small number of patients (to-
tal n = 22). Area under the ROC curve for NLR was 0.852 
(95% confidence interval: 0.814-0.885), with an optimal 
cut-off value of 2.71, sensitivity of 77.05%, and specificity 
of 87.23%. Area under the ROC curve for PLR was 0.753 
(95% confidence interval: 0.709-0.794), with an optimal 
cut-off value of 182.31, sensitivity of 51.09%, and specific-
ity of 91.49%.
TaBLe 1. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) values in lung carcinoma (LC) patients, divided 
into subtypes, and in the control group summarized as median with absolute range
Group N (%) NLR PLR
Lung cancer
small-cells LC (SCLC)*†  38 (9.8) 3.70 (1.15-23.07) 197.76 (16.36-464.29)
adenocarcinoma (NSCLC)*† 171 (44.1) 3.82 (1.04-24.75) 184.00 (30.70-637.04)
planocellular LC (NSCLC)* 120 (30.9) 3.67 (0.97-31.33) 171.63 (33.75-1006.67)
non-classified LC (NSCLC)*  37 (9.5) 4.71 (1.50-12.04) 206.43 (88.10-507.00)
metastatic or atypical LC  13 (3.4) 3.14 (1.64-11.47) 169.23 (76.43-313.33)
neuroendocrine LC   7 (1.8) 3.00 (2.31-8.80) 129.75 (108.46-421.10)
sarcomatoid LC   2 (0.5) 6.18, 7.10 170.59, 267.27
total 388 (100.0) 3.63 (0.97-31.33) 171 (16.36-1006.67)
Controls  47 (100.0) 2.07 (1.15-5.19) 115.00 (5.44-332.14)
P (aNOVa) <0.001 <0.001
*Significantly different compared to controls.
†SCLC – small cells lung carcinoma; NSCLC – non-small cells lung carcinoma.
FIGuRe 1. Receiver operating curve (ROC) for neutrophil-to-
lymphocyte ratio (A) and platelet-to-lymphocyte ratio (B).
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If we combine the cut-off value for NLR and PLR together, 
there is 80.85% chance that a healthy individual will not 
have LC if both ratios are under the cut-off value and there 
is 78.96% chance that an LC patient will have any type of LC 
if one or both ratios are above the cut-off value.
DISCuSSION
Our research shows that NLR and PLR in patients with dif-
ferent pathohistologic LC subtypes are significantly higher 
than in controls. Also, this study showed that NLR and PLR 
have satisfying diagnostic value in diagnosis of LC.
These findings are consistent with similar previous research, 
which showed an association between inflammatory tumor 
growth progression and disease outcome (7-13). Inflamma-
tion contributes to the LC pathogenesis and development 
(3), and increased neutrophil infiltration with decreased 
lymphocyte infiltration in the tumor tissue is associated 
with a poor survival and response to therapy in some LC 
subtypes (8-12). In their meta-analyses, Peng et al (7) and 
Gun et al (8) showed an association between NLR and the 
clinical outcome of NSCLC. They showed that a high base-
line NLR was associated with a poor overall survival and re-
sponse to chemotherapy. Therefore, NLR could be useful in 
creating an individual patient therapy plan (7,8). Although 
DBC components are non-specific parameters for cancer 
diagnosis and prognosis, using their ratios (NLR and PLR) 
could be a new approach to early LC diagnostics.
Our research showed that there were no significant differ-
ences in NLR and PLR between patients with different LC 
subtypes, although such differences are expectable due to 
different invasiveness of the specific LC subtypes (14).
The evaluation of the diagnostic sensitivity and specificity 
of NLR and PLR using ROC analysis showed that the opti-
mal NLR cutoff value was 2.71, and the optimal PLR cutoff 
value was 182.31. The area under the ROC curve showed 
that the cutoff NLR value (0.852) was more accurate in dis-
criminating between LC patients and healthy controls than 
the PLR cutoff value (0.753). Better sensitivity of the NLR 
(77.05%) indicates that it is a better marker for the diagno-
sis of LC. Although sensitivity and specificity of both mark-
ers are quite satisfying, by combining them, and including 
other known markers, we could increase the sensitivity 
and specificity of the LC diagnostic process.
Increased PLR is a direct consequence of the increased 
platelet number, due to their possible role in tumor 
growth through the mechanisms of immunomodulation 
and angiogenesis (3). Platelets stimulate tumor growth by 
reinforcing angiogenesis via cytokines, the vascular en-
dothelial growth factor, and platelet-derived growth factor. 
Tumors, by secreting factors that retain platelets, protect 
the environment that positively affects their survival (15). 
Through an interaction with the aforementioned platelet 
factors, tumors stimulate migration, proliferation, and epi-
thelio-mesenchymal transition of other cells (10).
Neutrophils can promote tumor growth and metastasis by 
inhibiting the function of the cytotoxic lymphocytes and 
remodeling the tumor extracellular matrix. The number of 
neutrophils also increases with an increase in the number 
of tumor cells (6). Therefore, it is logical to expect an in-
creased NLR, which is a systemic inflammatory index, in 
LC patients compared to the healthy population. In LC pa-
tients, the NLR reflects an imbalance in the pro- and anti-
tumor activities of the immunologic response (16).
Lymphocytes play an important role in tumor protection 
by decreasing tumor-cell proliferation and migration. How-
ever, an increase in the neutrophil count, as an organism`s 
response to tumor presence, diminishes the cytolytic activ-
ity of lymphocytes and natural killer cells and suppresses 
the proliferation of T-cells (17). Neutrophil presence in the 
tumor micro-surroundings directly increases its survival, 
which has a negative impact on the organism (10).
Our research, conducted on a relatively large number 
of participants, and with an appropriate referent popu-
lation, confirmed the results of previous research that 
showed an association between the inflammatory reac-
tion and LC (18). Although previous studies assessed the 
association between the NLR and PLR with the disease 
prognosis, therapy outcome, and response to therapy in 
NSCLC patients, our research was the first to include all 
other pathohistological LC subtypes in the assessment of 
the diagnostic significance of NLR and PLR. The cutoff val-
ues for NLR>2.71 and PLR>182.31 could be considered 
in the future when diagnosing LC. These ratios have the 
advantage of being easily obtainable without additional 
costs during the initial patient assessment when a cer-
tain disease is suspected, which is important for the ear-
ly diagnosis of LC. Results of the current research show 
that there is a significant difference in NLR and PLR be-
tween LC patients and healthy patients, but not between 
patients with different LC subtypes, which all points to 
the fact that NLR and PLR could be used only as general 
markers of the occurrence and development of LC, but 
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not as markers of the occurrence and development of 
certain LC subtypes.
Although this study showed a good diagnostic value of 
NLR and PLR in LC diagnosis, which is a novelty in this field, 
it has some limitations. First, the patient inclusion criteria 
did not involve the stage of LC but only patohistologycal 
type. Also, we did not compare these data with the group 
of patients with other malignant diseases or similar con-
ditions. Finally, different methodology in determination of 
DBC was used.
Future research on the diagnostic specificity and sensitiv-
ity of NLR and PLR should be made in combination with 
current LC markers, such as the cytokeratin fragment 21-1, 
neuron specific enolase, and alpha fetoprotein. It is pos-
sible that combination of the current markers could lead to 
a greater diagnostic sensitivity and specificity.
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